Back to Authors

Dürr, Alexandra

0000-0002-8921-7104

A5027293126 | I1294671590

Mayo Clinic

Centre National de la Recherche Scientifique

Citations 9

Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells

Movement Disorders | March 12, 2025 | Volume: 40 | Issue: 5 | Pages: 950-961

10.1002/mds.30150 | PMID 40055946

AbstractBackgroundThe 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP).ObjectiveTo investigate the association between CNVs and structural forms on 17q.21.31 with the risk of PSP.MethodsUtilizing whole genome sequencing data from 1684 PSP cases and 2392 controls, the three large CNVs (α, β, and γ) and structural forms within 17q21.31 were identified and analyzed for their association with PSP.ResultsWe found that the copy number of γ was associated with increased PSP risk (odds ratio [OR] = 1.10, P = 0.0018). From H1β1γ1 (OR = 1.21) and H1β2γ1 (OR = 1.24) to H1β1γ4 (OR = 1.57), structural forms of H1 with additional copies of γ displayed a higher risk for PSP. The frequency of the risk sub‐haplotype H1c rises from 1% in individuals with two γ copies to 88% in those with eight copies. Additionally, γ duplication up‐regulates expression of ARL17B, LRRC37A/LRRC37A2, and NSFP1, while down‐regulating KANSL1. Single‐nucleus RNA‐seq of the dorsolateral prefrontal cortex analysis reveals γ duplication primarily up‐regulates LRRC37A/LRRC37A2 in neuronal cells.ConclusionsThe copy number of γ is associated with the risk of PSP after adjusting for H1/H2, indicating that the complex structure at 17q21.31 is an important consideration when evaluating the genetic risk of PSP. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Genome-wide association analysis identifies PLA2G4C as a susceptibility locus for Multiple System Atrophy

No container title available | February 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3461290/v1

Abstract To elucidate the molecular basis of multiple system atrophy (MSA), a neurodegenerative disease, we conducted a genome-wide association study (GWAS) in a Japanese MSA case/control series followed by replication studies in Japanese, Korean, Chinese, European, and North American samples. In the GWAS stage, rs2303744 on chromosome 19 showed a suggestive association (P = 6.5 × 10− 7) that was replicated in additional Japanese samples (P = 2.9 × 10− 6, odds ratio (OR) = 1.58; 95% confidence interval (CI), 1.30–1.91), and then confirmed as highly significant in a meta-analysis of East Asian population data (P = 5.0 × 10− 15, OR = 1.49; 95% CI 1.35–1.65). The association of rs2303744 with MSA remained significant in combined European/North American samples (P = 0.017, OR = 1.12; 95% CI 1.02–1.23) despite allele frequencies being quite different between these populations. rs2303744 leads to an amino acid substitution in PLA2G4C that encodes the cPLA2γ lysophospholipase/transacylase. The cPLA2γ-Ile143 isoform encoded by the MSA risk allele has significantly decreased transacylase activity compared with the alternate cPLA2γ-Val143 isoform, and may perturb membrane phospholipids and promote oligodendroglial pathology.
Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

No container title available | March 18, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-322430/v1

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a life-time risk of 1 in 350 people and an unmet need for disease-modifying therapies. We conducted a cross-ancestry GWAS in ALS including 29,612 ALS patients and 122,656 controls which identified 15 risk loci in ALS. When combined with 8,953 whole-genome sequenced individuals (6,538 ALS patients, 2,415 controls) and the largest cortex-derived eQTL dataset (MetaBrain), analyses revealed locus-specific genetic architectures in which we prioritized genes either through rare variants, repeat expansions or regulatory effects. ALS associated risk loci were shared with multiple traits within the neurodegenerative spectrum, but with distinct enrichment patterns across brain regions and cell-types. Of the environmental and life-style risk factors obtained from literature, Mendelian randomization analyses indicated a causal role for high cholesterol levels. All ALS associated signals combined reveal a role for perturbations in vesicle mediated transport and autophagy, and provide evidence for cell-autonomous disease initiation in glutamatergic neurons.
2018: Year in Review and Message from the Editors to Our Reviewers

Neurology Genetics | February 15, 2019 | Volume: 5 | Issue: 1 | Pages: No page available

10.1212/nxg.0000000000000309

Variants associated with Gaucher disease in multiple system atrophy

Annals of Clinical and Translational Neurology | February 28, 2015 | Volume: 2 | Issue: 4 | Pages: 417-426

10.1002/acn3.185 | PMID 25909086

Large-scale replication and heterogeneity in Parkinson disease genetic loci

Neurology | July 12, 2012 | Volume: 79 | Issue: 7 | Pages: 659-667

10.1212/wnl.0b013e318264e353 | PMID 22786590

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

Neurology | February 9, 2012 | Volume: 78 | Issue: 10 | Pages: 690-695

10.1212/wnl.0b013e318249f683 | PMID 22323755

Second consensus statement on the diagnosis of multiple system atrophy

Neurology | August 25, 2008 | Volume: 71 | Issue: 9 | Pages: 670-676

10.1212/01.wnl.0000324625.00404.15 | PMID 18725592

P3–159: MAPT H1 subhaplotyping in european PD association samples implicates tau splicing in early–onset parkinson's disease susceptibility

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_14 | Pages: No page available

10.1016/j.jalz.2006.05.1427